https://news.medxy.ai/zh/mlh1-%e5%90%af%e5%8a%a8%e5%ad%90%e9%ab%98%e7%94%b2%e5%9f%ba%e5%8c%96%e4%b8%8d%e5%bd%b1%e5%93%8d-dmmr-%e5%ad%90%e5%ae%ab%e5%86%85%e8%86%9c%e7%99%8c%e6%8e%a5%e5%8f%97%e5%85%8d%e7%96%ab%e6%a3%80%e6%9f%a5/Medxy AIzh2026-08-01T09:53:38-07:00MLH1 启动子高甲基化不影响 dMMR 子宫内膜癌接受免疫检查点抑制剂治疗的生存结局 https://news.medxy.ai/ja/mlh1%e3%83%97%e3%83%ad%e3%83%a2%e3%83%bc%e3%82%bf%e3%83%bc%e9%ab%98%e3%83%a1%e3%83%81%e3%83%ab%e5%8c%96%e3%81%af%e3%80%81dmmr%e5%ad%90%e5%ae%ae%e5%86%85%e8%86%9c%e7%99%8c%e3%81%ab%e3%81%8a%e3%81%91/Medxy AIja2026-08-01T09:53:21-07:00MLH1プロモーター高メチル化は、dMMR子宮内膜癌における免疫チェックポイント阻害療法後の生存に影響しない https://news.medxy.ai/vi/tang-methyl-hoa-promoter-mlh1-khong-lam-thay-doi-tien-luong-song-con-o-ung-thu-noi-mac-tu-cung-dmmr-dieu-tri-bang-thuoc-uc-che-diem-kiem-soat-mien-dich/Medxy AIvi2026-08-01T09:53:03-07:00Tăng methyl hóa promoter MLH1 không làm thay đổi tiên lượng sống còn ở ung thư nội mạc tử cung dMMR điều trị bằng thuốc ức chế điểm kiểm soát miễn dịch https://news.medxy.ai/mlh1-promoter-hypermethylation-does-not-impact-survival-outcomes-in-dmmr-endometrial-cancer-treated-with-immune-checkpoint-inhibitors/Medxy AIen2026-08-01T09:51:47-07:00MLH1 Promoter Hypermethylation Does Not Impact Survival Outcomes in dMMR Endometrial Cancer Treated with Immune Checkpoint Inhibitors https://news.medxy.ai/zh/medical-mistrust-and-patient-in-obgyn-care/Medxy AIzh2026-08-01T08:18:56-07:00弥合信任鸿沟：解读妇产科诊疗中的医疗不信任与患者体验 https://news.medxy.ai/ja/medical-mistrust-and-patient-in-ob-gyn-care/Medxy AIja2026-08-01T08:18:41-07:00OB/GYN診療における医療不信と患者体験を読み解く：分断をつなぐ視点 https://news.medxy.ai/vi/bridging-the-gap-understanding-medical-mistrust-and-patient-in-ob-gyn-care/Medxy AIvi2026-08-01T08:18:22-07:00Thu hẹp khoảng cách: Hiểu về ngờ vực y khoa và trải nghiệm của người bệnh trong chăm sóc OB/GYN https://news.medxy.ai/bridging-the-gap-understanding-medical-mistrust-and-patient-experiences-in-ob-gyn-care/Medxy AIen2026-08-01T08:16:21-07:00Bridging the Gap: Understanding Medical Mistrust and Patient Experiences in OB/GYN Care https://news.medxy.ai/zh/placenta-accreta-spectrum-a-topography-guided-approach-to-prenatal-imaging-and-surgical-management/Medxy AIzh2026-07-31T15:01:57-07:00重新审视胎盘植入谱系：基于拓扑分布的产前影像评估与个体化手术管理 https://news.medxy.ai/ja/placenta-accreta-spectrum-a-topography-guided-to-prenatal-imaging-and-tailored-surgical-management/Medxy AIja2026-07-31T15:01:40-07:00癒着胎盤スペクトラムを再考する：出生前画像診断と個別化手術管理へのトポグラフィー主導アプローチ https://news.medxy.ai/vi/placenta-accreta-spectrum-a-topography-guided-approach-to-prenatal-imaging-and-tailored-surgical-management/Medxy AIvi2026-07-31T15:01:20-07:00Nhìn lại hội chứng nhau cài răng lược: Tiếp cận theo địa hình để chẩn đoán hình ảnh trước sinh và xử trí phẫu thuật cá thể hóa https://news.medxy.ai/rethinking-placenta-accreta-spectrum-a-topography-guided-approach-to-prenatal-imaging-and-tailored-surgical-management/Medxy AIen2026-07-31T15:00:32-07:00Rethinking Placenta Accreta Spectrum: A Topography-Guided Approach to Prenatal Imaging and Tailored Surgical Management https://news.medxy.ai/zh/disparities-and-persistence-in-systemic-hormone-therapy-in-menopausal-women/Medxy AIzh2026-07-31T14:17:36-07:00绝经女性全身性激素治疗的差异与持续性：来自大规模真实世界分析的启示 https://news.medxy.ai/vi/disparities-and-persistence-in-systemic-hormone-therapy-among-menopausal-women/Medxy AIvi2026-07-31T14:16:50-07:00Chênh lệch và mức độ duy trì liệu pháp hormone toàn thân ở phụ nữ mãn kinh: Góc nhìn từ một phân tích thực tế quy mô lớn https://news.medxy.ai/disparities-and-persistence-in-systemic-hormone-therapy-among-menopausal-women-insights-from-a-large-real-world-analysis/Medxy AIen2026-07-31T14:16:04-07:00Disparities and Persistence in Systemic Hormone Therapy Among Menopausal Women: Insights from a Large Real-World Analysis https://news.medxy.ai/zh/ripply1-in-ctnnb1-mutated-hepatocellular-carcinoma/Medxy AIzh2026-07-31T13:35:27-07:00RIPPLY1：CTNNB1突变型肝细胞癌中的“守护者” https://news.medxy.ai/ja/ripply1-against-cancer-in-ctnnb1-mutated-hepatocellular-carcinoma/Medxy AIja2026-07-31T13:35:05-07:00CTNNB1変異肝細胞癌におけるがん幹細胞性の抑制因子RIPPLY1の役割 https://news.medxy.ai/vi/ripply1-against-cancer-stemness-in-ctnnb1-mutated-hepatocellular-carcinoma/Medxy AIvi2026-07-31T13:34:43-07:00RIPPLY1: “lá chắn” chống tính chất tế bào gốc ung thư trong ung thư biểu mô tế bào gan mang đột biến CTNNB1 https://news.medxy.ai/ripply1-as-a-guardian-against-cancer-stemness-in-ctnnb1-mutated-hepatocellular-carcinoma/Medxy AIen2026-07-31T13:33:47-07:00RIPPLY1 as a Guardian Against Cancer Stemness in CTNNB1-Mutated Hepatocellular Carcinoma https://news.medxy.ai/zh/masld-sex-specific-endotypes-and-mortality/Medxy AIzh2026-07-31T13:14:33-07:00蛋白组学揭示MASLD：性别特异性内表型及其死亡预测价值 https://news.medxy.ai/ja/masld-sex-specific-endotypes-and-predictive-for-mortality/Medxy AIja2026-07-31T13:14:14-07:00MASLDのプロテオーム解析が解き明かす性差エンドタイプと死亡予測能 https://news.medxy.ai/vi/masld-sex-specific-endotypes-and-predictive-value-for-mortality/Medxy AIvi2026-07-31T13:13:52-07:00Proteomics hé lộ MASLD: các endotype đặc hiệu theo giới và giá trị dự báo tử vong https://news.medxy.ai/proteomic-insights-into-masld-sex-specific-endotypes-and-predictive-value-for-mortality/Medxy AIen2026-07-31T13:13:02-07:00Proteomic Insights into MASLD: Sex-Specific Endotypes and Predictive Value for Mortality https://news.medxy.ai/zh/colorectal-cancer-prognostication-validating-enhanced-ai-for-risk-stratification/Medxy AIzh2026-07-31T13:11:55-07:00AI 赋能 II 期结直肠癌预后评估：语义增强模型助力风险分层优化 https://news.medxy.ai/ja/colorectal-cancer-prognostication-validating-semantically-enhanced-ai-for-risk-stratification/Medxy AIja2026-07-31T13:11:34-07:00stage II大腸癌の予後予測を変える：意味論的強化AIによるリスク層別化の検証 https://news.medxy.ai/vi/stage-ii-colorectal-cancer-prognostication-validating-semantically-enhanced-ai-for-risk-stratification/Medxy AIvi2026-07-31T13:11:11-07:00Tái định hình tiên lượng ung thư đại trực tràng giai đoạn II: Thẩm định AI tăng cường ngữ nghĩa cho phân tầng nguy cơ https://news.medxy.ai/revolutionizing-stage-ii-colorectal-cancer-prognostication-validating-semantically-enhanced-ai-for-risk-stratification/Medxy AIen2026-07-31T13:10:24-07:00Revolutionizing Stage II Colorectal Cancer Prognostication: Validating Semantically-Enhanced AI for Risk Stratification https://news.medxy.ai/zh/blood-pressure-endovascular-thrombectomy-risks-of-acute-kidney-injury/Medxy AIzh2026-07-31T13:03:10-07:00血管内取栓术后血压如何平衡：急性肾损伤风险与卒中康复结局 https://news.medxy.ai/ja/blood-pressure-after-endovascular-thrombectomy-risks-of-acute-kidney-injury/Medxy AIja2026-07-31T13:02:53-07:00経血管的血栓除去術後の血圧管理：急性腎障害リスクと脳卒中回復への影響 https://news.medxy.ai/vi/blood-pressure-after-endovascular-thrombectomy-risks-of-acute-kidney-injury-and-impact-on-stroke-recovery/Medxy AIvi2026-07-31T13:02:34-07:00Cân bằng huyết áp sau lấy huyết khối nội mạch: nguy cơ tổn thương thận cấp và ảnh hưởng đến hồi phục sau đột quỵ https://news.medxy.ai/balancing-blood-pressure-after-endovascular-thrombectomy-risks-of-acute-kidney-injury-and-impact-on-stroke-recovery/Medxy AIen2026-07-31T13:01:36-07:00Balancing Blood Pressure After Endovascular Thrombectomy: Risks of Acute Kidney Injury and Impact on Stroke Recovery https://news.medxy.ai/zh/decoding-sleeps-role-in-cognitive-health-and-dementia-risk/Medxy AIzh2026-07-31T12:58:48-07:00解析睡眠在认知健康与痴呆风险中的作用：来自睡眠与痴呆联盟的研究见解 https://news.medxy.ai/decoding-sleeps-role-in-cognitive-health-and-dementia-risk-insights-from-the-sleep-and-dementia-consortium/Medxy AIen2026-07-31T12:57:20-07:00Decoding Sleep’s Role in Cognitive Health and Dementia Risk: Insights from the Sleep and Dementia Consortium https://news.medxy.ai/zh/pemetrexed-monotherapy-and-combination-with-carboplatin-in-advanced-thyroid-cancer/Medxy AIzh2026-07-31T12:56:08-07:00晚期甲状腺癌中培美曲塞单药及联合卡铂治疗的疗效评估：一项回顾性队列分析 https://news.medxy.ai/ja/pemetrexed-monotherapy-and-combination-therapy-with-carboplatin-in-advanced-thyroid-cancer/Medxy AIja2026-07-31T12:55:53-07:00進行性甲状腺癌に対するpemetrexed単剤療法とcarboplatin併用療法の評価：後ろ向きコホート解析 https://news.medxy.ai/vi/pemetrexed-monotherapy-and-combination-therapy-with-carboplatin-in-advanced-thyroid-cancer-a-retrospective-cohort-analysis/Medxy AIvi2026-07-31T12:55:34-07:00Đánh giá pemetrexed đơn trị và phối hợp carboplatin trong ung thư tuyến giáp tiến triển: phân tích đoàn hệ hồi cứu https://news.medxy.ai/evaluating-pemetrexed-monotherapy-and-combination-therapy-with-carboplatin-in-advanced-thyroid-cancer-a-retrospective-cohort-analysis/Medxy AIen2026-07-31T12:54:35-07:00Evaluating Pemetrexed Monotherapy and Combination Therapy with Carboplatin in Advanced Thyroid Cancer: A Retrospective Cohort Analysis https://news.medxy.ai/ja/dapagliflozin-and-lipoprotein-metabolism-in-t2dm-preserving-ldl-catabolism-and-vldl-processing/Medxy AIja2026-07-31T12:53:41-07:00ダパグリフロジンは2型糖尿病の脂質代謝をどう変えるか：LDL分解を保ちつつVLDL処理を正常化する https://news.medxy.ai/vi/dapagliflozin-and-lipoprotein-metabolism-in-t2dm-preserving-ldl-catabolism-and-normalizing-vldl-processing/Medxy AIvi2026-07-31T12:53:18-07:00Dapagliflozin và chuyển hóa lipoprotein trong đái tháo đường type 2: bảo tồn dị hóa LDL và đưa xử lý VLDL về gần sinh lý bình thường https://news.medxy.ai/dapagliflozin-and-lipoprotein-metabolism-in-type-2-diabetes-preserving-ldl-catabolism-and-normalizing-vldl-processing/Medxy AIen2026-07-31T12:52:26-07:00Dapagliflozin and Lipoprotein Metabolism in Type 2 Diabetes: Preserving LDL Catabolism and Normalizing VLDL Processing https://news.medxy.ai/zh/insulin-pump-therapy-on-hospital-readmissions-and-mortality-in-adults-with-t1dm/Medxy AIzh2026-07-31T08:35:34-07:00胰岛素泵治疗对1型糖尿病成人再入院率和住院死亡率的影响：基于2022年全国性分析的启示 https://news.medxy.ai/ja/insulin-pump-therapy-on-hospital-readmissions-and-mortality-in-adults-with-type-1-diabetes/Medxy AIja2026-07-31T08:35:13-07:001型糖尿病成人におけるインスリンポンプ療法と再入院・死亡への影響：2022年全国解析からの知見 https://news.medxy.ai/vi/insulin-pump-therapy-and-its-impact-on-hospital-readmissions-and-mortality-in-adults-with-type-1-diabetes/Medxy AIvi2026-07-31T08:34:51-07:00Liệu pháp bơm insulin ở người lớn mắc đái tháo đường type 1: tác động lên tái nhập viện và tử vong trong bệnh viện qua phân tích toàn quốc năm 2022 https://news.medxy.ai/insulin-pump-therapy-and-its-impact-on-hospital-readmissions-and-mortality-in-adults-with-type-1-diabetes-insights-from-a-2022-nationwide-analysis/Medxy AIen2026-07-31T08:33:27-07:00Insulin Pump Therapy and Its Impact on Hospital Readmissions and Mortality in Adults with Type 1 Diabetes: Insights from a 2022 Nationwide Analysis https://news.medxy.ai/zh/diagnostic-tools-for-peripheral-arterial-disease-in-diabetes-1/Medxy AIzh2026-07-30T16:22:21-07:00重新审视糖尿病外周动脉疾病的诊断工具：DMPAD研究带来的启示 https://news.medxy.ai/ja/diagnostic-tools-for-peripheral-arterial-disease-in-diabetes/Medxy AIja2026-07-30T16:22:06-07:00糖尿病における末梢動脈疾患の診断再考：DMPAD研究が示す臨床課題 https://news.medxy.ai/vi/reassessing-diagnostic-tools-for-peripheral-arterial-disease-in-diabetes/Medxy AIvi2026-07-30T16:21:47-07:00Đánh giá lại công cụ chẩn đoán bệnh động mạch ngoại biên ở người bệnh đái tháo đường: Phát hiện từ nghiên cứu DMPAD https://news.medxy.ai/reassessing-diagnostic-tools-for-peripheral-arterial-disease-in-diabetes-insights-from-the-dmpad-study/Medxy AIen2026-07-30T16:21:09-07:00Reassessing Diagnostic Tools for Peripheral Arterial Disease in Diabetes: Insights from the DMPAD Study https://news.medxy.ai/zh/acoramidis-improves-heart-failure-related-quality-of-life-in-transthyretin-amyloid-cardiomyopathy/Medxy AIzh2026-07-30T15:53:47-07:00Acoramidis 显著改善转甲状腺素蛋白淀粉样心肌病患者的心力衰竭相关生活质量：来自 ATTRibute-CM 试验的启示 https://news.medxy.ai/ja/acoramidis-significantly-improves-heart-failure-related-quality-of-life-in-transthyretin-amyloid-cardiomyopathy/Medxy AIja2026-07-30T15:53:31-07:00アコラミジス、ATTR-CMのQOLを有意に改善　ATTRibute-CM試験が示した心不全関連アウトカムへの効果 https://news.medxy.ai/acoramidis-significantly-improves-heart-failure-related-quality-of-life-in-transthyretin-amyloid-cardiomyopathy-insights-from-the-attribute-cm-trial/Medxy AIen2026-07-30T15:52:23-07:00Acoramidis Significantly Improves Heart Failure-Related Quality of Life in Transthyretin Amyloid Cardiomyopathy: Insights from the ATTRibute-CM Trial https://news.medxy.ai/zh/jcad-protein-for-residual-cardiovascular-risk/Medxy AIzh2026-07-30T15:42:22-07:00JCAD 蛋白：急性冠状动脉综合征残余心血管风险的新型预测因子与治疗靶点 https://news.medxy.ai/vi/jcad-protein-for-residual-cardiovascular-risk-in-acute-coronary-syndrome/Medxy AIvi2026-07-30T15:41:46-07:00JCAD: Dấu ấn sinh học và đích điều trị mới cho nguy cơ tim mạch tồn dư trong hội chứng vành cấp https://news.medxy.ai/jcad-protein-a-novel-predictor-and-therapeutic-target-for-residual-cardiovascular-risk-in-acute-coronary-syndrome/Medxy AIen2026-07-30T15:41:01-07:00JCAD Protein: A Novel Predictor and Therapeutic Target for Residual Cardiovascular Risk in Acute Coronary Syndrome https://news.medxy.ai/zh/evidence-generation-and-translation-of-anticoagulation-strategies-in-noncritically-ill-covid-19/Medxy AIzh2026-07-30T15:36:38-07:00拨开不确定性：非重症 COVID-19 患者抗凝策略的快速证据生成与转化 https://news.medxy.ai/ja/navigating-uncertainty-rapid-evidence-generation-and-translation-of-anticoagulation-strategies-in-noncritically-ill-covid-19/Medxy AIja2026-07-30T15:36:22-07:00不確実性を乗り越える：非重症COVID-19患者における抗凝固戦略の迅速なエビデンス創出と臨床応用 https://news.medxy.ai/vi/evidence-generation-and-translation-of-anticoagulation-strategies-in-noncritically-ill-covid-19-patients/Medxy AIvi2026-07-30T15:36:04-07:00Vượt qua bất định: Tạo bằng chứng nhanh và chuyển hóa chiến lược chống đông ở bệnh nhân COVID-19 nhập viện nhưng không nguy kịch https://news.medxy.ai/navigating-uncertainty-rapid-evidence-generation-and-translation-of-anticoagulation-strategies-in-noncritically-ill-covid-19-patients/Medxy AIen2026-07-30T15:35:23-07:00Navigating Uncertainty: Rapid Evidence Generation and Translation of Anticoagulation Strategies in Noncritically Ill COVID-19 Patients https://news.medxy.ai/ja/risk-guided-screening-for-atrial-fibrillation/Medxy AIja2026-07-30T15:28:57-07:00電子健康記録で心房細動を拾い上げる：リスク層別化スクリーニングの新戦略 https://news.medxy.ai/vi/screening-for-atrial-fibrillation-using-electronic-health-records/Medxy AIvi2026-07-30T15:28:40-07:00Sàng lọc rung nhĩ theo nguy cơ bằng hồ sơ sức khỏe điện tử https://news.medxy.ai/risk-guided-screening-for-atrial-fibrillation-using-electronic-health-records/Medxy AIen2026-07-30T15:28:03-07:00Risk-Guided Screening for Atrial Fibrillation Using Electronic Health Records https://news.medxy.ai/ja/survival-in-unresectable-hepatocellular-carcinoma-with-combined-transarterial-chemoembolization-and-thermal-ablation-insights-from-the-phase-3-torch-trial/Medxy AIja2026-07-30T15:18:05-07:00切除不能肝細胞癌に対する肝動脈化学塞栓療法と熱焼灼療法の併用で生存成績が改善：第3相TORCH試験の知見 https://news.medxy.ai/vi/improved-survival-in-unresectable-hepatocellular-carcinoma-with-combined-transarterial-chemoembolization-and-thermal-ablation/Medxy AIvi2026-07-30T15:17:44-07:00Kết hợp TACE và đốt nhiệt giúp cải thiện sống còn ở ung thư biểu mô tế bào gan không thể cắt bỏ: Kết quả từ thử nghiệm giai đoạn 3 TORCH https://news.medxy.ai/improved-survival-in-unresectable-hepatocellular-carcinoma-with-combined-transarterial-chemoembolization-and-thermal-ablation-insights-from-the-phase-3-torch-trial/Medxy AIen2026-07-30T15:16:53-07:00Improved Survival in Unresectable Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Thermal Ablation: Insights from the Phase 3 TORCH Trial